Literature DB >> 31113615

Cancer upregulated gene 2 (CUG2), a novel oncogene, promotes stemness-like properties via the NPM1-TGF-β signaling axis.

Sirichat Kaowinn1, Eun Jin Seo2, Woong Heo3, Jae-Ho Bae3, Eun-Jung Park4, Soojin Lee5, Yeon Jeong Kim6, Sang Seok Koh6, Il Ho Jang7, Dong Hoon Shin8, Young-Hwa Chung9.   

Abstract

Our previous study reported that cancer upregulated gene (CUG)2, a novel oncogene, induces both faster cell migration and anti-cancer drug resistance. We thus wonder whether CUG2 also induces stemness, a characteristic of cancer stem cells (CSCs) and further examine the molecular mechanism of this phenotype. To test that CUG2 induces stemness, we examined expression of stemness-related factors. Overexpression of CUG2 enhanced expression levels of stemness-related factors in human lung carcinoma A549 and immortalized bronchial BEAS-2B cells. Consequently, CUG2 increased cellular spherical cluster forming ability. Overexpression of CUG2 also induced tumor formation in xenotransplanted nude mice whereas transplantation of control cells failed to, implying that CUG2 possesses malignant tumorigenic potential. We paid attention to nucleophosmin (NPM1) for its known interaction with CUG2. Suppression of NPM1 hindered the CUG2-mediated stemness-like phenotypes and diminished TGF-β transcriptional activity and signaling. TGF-β increased stemness-like phenotypes in the control cells whereas TGF-β inhibitor blocked induction of the phenotypes, indicating that NPM1 is required for CUG2-mediated stemness-like phenotypes through TGF-β signaling. Furthermore, the suppression of Smad- and non-Smad-dependent TGF-β signaling pathways also prevented CUG2 from inducing stemness-like phenotypes. Altogether, we suggest that the novel CUG2 oncogene promotes cellular transformation and stemness, mediated by nuclear NPM1 protein and TGF-β signaling.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CUG2; Cancer stem cell; NPM1; Stemness; TGF-β

Year:  2019        PMID: 31113615     DOI: 10.1016/j.bbrc.2019.05.091

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

2.  Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling.

Authors:  Natpaphan Yawut; Chutima Kaewpiboon; Phatcharaporn Budluang; Il-Rae Cho; Sirichat Kaowinn; Sang Seok Koh; Young-Hwa Chung
Journal:  Cancer Manag Res       Date:  2020-10-15       Impact factor: 3.989

3.  Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.

Authors:  Chun-Ming Ho; Kuen-Tyng Lin; Roger Shen; De-Leung Gu; Szu-Shuo Lee; Wen-Hui Su; Yuh-Shan Jou
Journal:  Comput Struct Biotechnol J       Date:  2022-04-09       Impact factor: 6.155

4.  Translocalization of enhanced PKM2 protein into the nucleus induced by cancer upregulated gene 2 confers cancer stem cell-like phenotypes.

Authors:  Natpaphan Yawut; Sirichat Kaowinn; Il-Rae Cho; Phatcharaporn Budluang; Seonghye Kim; Suhkmann Kim; So Eun Youn; Sang Seok Koh; Young-Hwa Chung
Journal:  BMB Rep       Date:  2022-02       Impact factor: 4.778

5.  LncRNA MBNL1-AS1 Represses Proliferation and Cancer Stem-Like Properties of Breast Cancer through MBNL1-AS1/ZFP36/CENPA Axis.

Authors:  Yu Ding; Yingjie Li; Yunqiang Duan; Wan Wang; Wei Zheng; Weilun Cheng; Yuan Qi; Jianyuan Feng; Ziang Chen; Tianshui Yu; Anbang Hu; Ting Wang; Mingcui Li; Hanyu Zhang; Yanling Li; Fei Ma; Baoliang Guo
Journal:  J Oncol       Date:  2022-04-26       Impact factor: 4.501

Review 6.  Cancer Stem Cells: From an Insight into the Basics to Recent Advances and Therapeutic Targeting.

Authors:  Shweta Bisht; Manisha Nigam; Shyam S Kunjwal; Plygun Sergey; Abhay Prakash Mishra; Javad Sharifi-Rad
Journal:  Stem Cells Int       Date:  2022-06-28       Impact factor: 5.131

7.  Investigating CENPW as a Novel Biomarker Correlated With the Development and Poor Prognosis of Breast Carcinoma.

Authors:  Luyang Wang; Hairui Wang; Chen Yang; Yunyi Wu; Guojie Lei; Yanhua Yu; Yan Gao; Jing Du; Xiangmin Tong; Feifei Zhou; Yanchun Li; Ying Wang
Journal:  Front Genet       Date:  2022-06-17       Impact factor: 4.772

8.  CENPO is Associated with Immune Cell Infiltration and is a Potential Diagnostic and Prognostic Marker for Hepatocellular Carcinoma.

Authors:  Kun He; Mengyi Xie; Jingdong Li; Yi He; Yaolin Yin
Journal:  Int J Gen Med       Date:  2022-09-25

Review 9.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

10.  Elevated Expression of JMJD5 Protein Due to Decreased miR-3656 Levels Contributes to Cancer Stem Cell-Like Phenotypes under Overexpression of Cancer Upregulated Gene 2.

Authors:  Natpaphan Yawut; Il-Rae Cho; Phatcharaporn Budluang; Sirichat Kaowinn; Chutima Kaewpiboon; Byeoleun Jeon; Sang-Woo Kim; Ho Young Kang; Min-Kyung Kang; Sang Seok Koh; Young-Hwa Chung
Journal:  Biomolecules       Date:  2022-01-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.